1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective
of the Study
2.2. Baseline
Methodology
2.3. Key Industry
Partners
2.4. Major
Association and Secondary Sources
2.5. Forecasting
Methodology
2.6. Data
Triangulation & Validation
2.7. Assumptions
and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5.
Global Genitourinary
Drugs Market Outlook
5.1. Market Size & Forecast
5.1.1.
By Value
5.2. Market Share & Forecast
5.2.1.
By Indication
(Prostate Cancer, Ovarian Cancer, Bladder Cancer, Cervical Cancer, Renal
Cancer, Erectile Dysfunction, Urinary Tract Infections, Urinary Incontinence
& Overactive Bladder, Sexually Transmitted Diseases, Interstitial Cystitis,
Hematuria, Benign Prostatic Hyperplasia)
5.2.2.
By Product (Hormonal Therapy,
Gynecological, Urologicals, Anti-infectives, others)
5.2.3.
By Region
5.2.4.
By Company (2022)
5.3. Market Map
6.
Asia Pacific Genitourinary
Drugs Market Outlook
6.1. Market Size & Forecast
6.1.1.
By Value
6.2. Market Share & Forecast
6.2.1.
By Indication
6.2.2.
By Product
6.2.3.
By Country
6.3. Asia Pacific: Country Analysis
6.3.1.
China Genitourinary
Drugs Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Indication
6.3.1.2.2.
By Product
6.3.2.
India Genitourinary
Drugs Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Indication
6.3.2.2.2.
By Product
6.3.3.
Australia Genitourinary
Drugs Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Indication
6.3.3.2.2.
By Product
6.3.4.
Japan Genitourinary
Drugs Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Indication
6.3.4.2.2.
By Product
6.3.5.
South Korea Genitourinary
Drugs Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Indication
6.3.5.2.2.
By Product
7.
Europe Genitourinary
Drugs Market Outlook
7.1. Market Size & Forecast
7.1.1.
By Value
7.2. Market Share & Forecast
7.2.1.
By Indication
7.2.2.
By Product
7.2.3.
By Country
7.3. Europe: Country Analysis
7.3.1.
France Genitourinary
Drugs Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Indication
7.3.1.2.2.
By Product
7.3.2.
Germany Genitourinary
Drugs Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Indication
7.3.2.2.2.
By Product
7.3.3.
Spain Genitourinary
Drugs Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Indication
7.3.3.2.2.
By Product
7.3.4.
Italy Genitourinary
Drugs Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Indication
7.3.4.2.2.
By Product
7.3.5.
United Kingdom Genitourinary
Drugs Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Indication
7.3.5.2.2.
By Product
8.
North America Genitourinary
Drugs Market Outlook
8.1. Market Size & Forecast
8.1.1.
By Value
8.2. Market Share & Forecast
8.2.1.
By Indication
8.2.2.
By Product
8.2.3.
By Country
8.3. North America: Country Analysis
8.3.1.
United States Genitourinary
Drugs Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Indication
8.3.1.2.2.
By Product
8.3.2.
Mexico Genitourinary
Drugs Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Indication
8.3.2.2.2.
By Product
8.3.3.
Canada Genitourinary
Drugs Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Indication
8.3.3.2.2.
By Product
9.
South America Genitourinary
Drugs Market Outlook
9.1. Market Size & Forecast
9.1.1.
By Value
9.2. Market Share & Forecast
9.2.1.
By Indication
9.2.2.
By Product
9.2.3.
By Country
9.3. South America: Country Analysis
9.3.1.
Brazil Genitourinary
Drugs Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Indication
9.3.1.2.2.
By Product
9.3.2.
Argentina Genitourinary
Drugs Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Indication
9.3.2.2.2.
By Product
9.3.3.
Colombia Genitourinary
Drugs Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Indication
9.3.3.2.2.
By Product
10.
Middle East and Africa
Genitourinary Drugs Market Outlook
10.1.
Market Size &
Forecast
10.1.1. By Value
10.2.
Market Share &
Forecast
10.2.1.
By Indication
10.2.2.
By Product
10.2.3. By Country
10.3.
MEA: Country
Analysis
10.3.1. South Africa Genitourinary Drugs Market Outlook
10.3.1.1. Market Size &
Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share &
Forecast
10.3.1.2.1.
By Indication
10.3.1.2.2.
By Product
10.3.2. Saudi Arabia Genitourinary Drugs Market Outlook
10.3.2.1. Market Size &
Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share &
Forecast
10.3.2.2.1.
By Indication
10.3.2.2.2.
By Product
10.3.3. UAE Genitourinary Drugs Market Outlook
10.3.3.1. Market Size &
Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share &
Forecast
10.3.3.2.1.
By Indication
10.3.3.2.2.
By Product
11. Market Dynamics
11.1.
Drivers
11.2.
Challenges
12. Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers &
Acquisitions
13. Global Genitourinary Drugs Market: SWOT Analysis
14.
Porter’s Five Forces
Analysis
14.1.
Competition in the
Industry
14.2.
Potential of New
Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute
Product
15. PESTLE Analysis
16. Competitive Landscape
16.1.
Abbott Laboratories
Ltd.
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products & Services
16.1.4. Financials (In case of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2.
Bristol-Myers Squibb Co.
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products & Services
16.2.4. Financials (In case of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3.
Novartis AG
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products & Services
16.3.4. Financials (In case of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4.
Genentech, Inc.
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products & Services
16.4.4. Financials (In case of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5.
F. Hoffmann-La Rochel Ltd.
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products & Services
16.5.4. Financials (In case of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6.
Ionis Pharmaceuticals, Inc.
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products & Services
16.6.4. Financials (In case of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7.
Eli Lilly and Company
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products & Services
16.7.4. Financials (In case of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8.
Merck & Co, Inc.
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products & Services
16.8.4. Financials (In case of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9.
Pfizer, Inc.
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products & Services
16.9.4. Financials (In case of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.AstraZeneca Plc.
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products & Services
16.10.4. Financials (In case of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17.
Strategic Recommendations
18.
About Us &
Disclaimer